Mergers & Acquisitions ·
Sangamo Therapeutics filed an amendment to a previous 8-K to include Asset Purchase Agreements dated June 22, 2026…
SGMOSangamo Therapeutics, Inc
Sangamo Therapeutics filed an amendment to a previous 8-K to include Asset Purchase Agreements dated June 22, 2026, with Eli Lilly and Company and Astellas Gene Therapies, Inc. The filing also references a Nasdaq delisting notification received April 28, 2026, due to minimum bid price non-compliance, which resulted in the common stock trading on the OTCQB Venture Market starting May 5, 2026. The company is a biotechnology company that develops therapeutic products for the treatment of genetic diseases.